Ibrutinib (Imbruvica®) for previously untreated CLL
Ibrutinib (Imbruvica®), as a single agent, is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This indication is an extension to the original licence in the relapsed/refractory setting.
Rapid Review
Commenced | Completed | Outcome |
02/08/2016 | 24/08/2016 | Full pharmacoeconomic evaluation recommended |
Not considered cost-effective due to non-submission of full pharmacoeconomic evaluation.